World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0000846403
Reproduction Date:

Title: Ergoloid  
Author: World Heritage Encyclopedia
Language: English
Subject: Dihydroergocryptine, Nootropics, Dihexa, Lecozotan, Bifemelane
Collection: Antidementia Agents, Gabaa Receptor Positive Allosteric Modulators, Lactams, Lysergamides, Nootropics, Oxazolopyrrolopyrazines
Publisher: World Heritage Encyclopedia


Combination of
Dihydroergocristine Ergot alkaloid
Dihydroergocornine Ergot alkaloid
alpha-Dihydroergocryptine Ergot alkaloid
beta-Dihydroergocryptine Ergot alkaloid
Clinical data
  • Contraindicated
Legal status
  • (Prescription only)
Routes of
Oral, parenteral
CAS Registry Number  Y
ATC code C04
DrugBank  Y

Ergoloid mesylates (USAN), co-dergocrine mesilate (BAN) or dihydroergotoxine mesylate, trade name Hydergine, is a mixture of the methanesulfonate salts of three dihydrogenated ergot alkaloids (dihydroergocristine, dihydroergocornine, and alpha- and beta-dihydroergocryptine).

It was developed by Albert Hofmann (the inventor of LSD) for Sandoz (now part of Novartis).


  • Uses 1
  • Mechanism of action 2
  • Contraindications 3
  • Adverse reactions 4
  • Chemistry 5
  • Trade names 6
  • References 7
  • External links 8


It has been used to treat dementia and age-related cognitive impairment (such as in Alzheimer disease),[1] as well as to aid in recovery after stroke.

There is some evidence suggesting that potentially effective doses may be higher than those currently approved in dementia treatment.[2]

Ergoloids are also used by many people as a nootropic. It may be used in conjunction with other cerebral enhancers like piracetam, with which it may act synergistically.[3]

Ergoloid Mesylate Tablets USP for sublingual use contain 1 mg of Ergoloid Mesylates USP, a mixture of the methanesulfonate salt of the following hydrogenated alkaloids: Dihydroergocornine mesylate 0.333 mg, Dihydroergocristine mesylate 0.333 mg, Dihydroergocryptine mesylate 0.333 mg.[4]

Mechanism of action

Despite the fact that hydergine has been used in the treatment of dementia for many years, its mechanism of action is still not clear.[5] It stimulates dopaminergic and serotonergic receptors and blocks alpha-adrenoreceptors.[6] Current studies imply that the major effect of hydergine may be the modulation of synaptic neurotransmission rather than solely increasing blood flow as was once thought.[7] A prominent feature that accompanies aging is an increase in monoamine oxidase (MAO) levels.[8] This results in decreased availability of catecholamines in the synaptic cleft. In one study, an interaction between age and hydergine treatment was observed in the hypothalamus, hippocampus and cerebellum. The hydergine effect was more pronounced in the aged group in the hypothalamus and cerebellum, and more pronounced in the adult in the hippocampus. These findings imply that increased brain MAO activity in aging can be modified by hydergine treatment in some brain regions.


Ergoloid is contraindicated in individuals who have previously shown hypersensitivity to the drug. They are also contraindicated in patients who have psychosis, acute or chronic, regardless of etiology.[9] Specific drug interactions are unknown but it has been claimed that there are multiple potential interactions.[9]

Adverse reactions

Adverse effects are minimal. The most common include transient, dose dependent nausea and gastrointestinal disturbances,[5] and sublingual irritation with SL tablets. Other common side effects include:[9][10]

As a result of the last-mentioned effects, the use of ergot derivatives for the treatment of blood circulation disorders, memory problems, sensation problems and the treatment of migraine is no longer permitted in some EU countries because the risks are believed to outweigh any benefits.[11]


The four constituents differ only in which of four proteinogenic amino acids is used in biosynthesis:[13]

Compound Amino acid
Dihydroergocristine Phenylalanine
Dihydroergocornine Valine
alpha-Dihydroergocryptine Leucine
beta-Dihydroergocryptine Isoleucine

Trade names

Hydergine, Hydergina, Gerimal, Niloric, Redizork, Alkergot, Cicanol, Redergin.


  1. ^ Flynn, B. L.; Ranno, A. E. (February 1999). "Pharmacologic Management of Alzheimer Disease, Part II: Antioxidants, Antihypertensives, and Ergoloid Derivatives". Annals of Pharmacotherapy 33 (2): 188–197.  
  2. ^ Schneider, L. S.; Olin, J. T. (August 1994). "Overview of Clinical Trials of Hydergine in Dementia". Archives of Neurology 51 (8): 787–798.  
  3. ^ Pearson, D.; Shaw, S. (1982). "Part III Chapter 2 : Revitalizing Your Brain Power". Life Extension - A Practical Scientific Approach. Warner Books.  
  4. ^ Ergoloid ( . Retrieved 08-02-2013.
  5. ^ a b Schiff, Paul L, Jr (2006) "Ergot and Its Alkaloids", American Journal of Pharmaceutical Education 70.5 p.98.
  6. ^ Markstein, R. (1985). "Hydergine: Interaction with the Neurotransmitter Systems in the Central Nervous System". Journal of Pharmacology 16 (Suppl 3): 1–17.  
  7. ^ Rowell et al. (Jul 1999) "Ergocryptine and other ergot alkaloids stimulate the release of [3H] dopamine from rat striatal synaptosomes", Journal of Animal Science 77.7 pp.1800-6
  8. ^ Kennedy et al. (Dec 2000) "Suicide and Aging: International Perspectives", Psychiatric Quarterly 71.4 pp.345-62
  9. ^ a b c "Drugs to Treat Alzheimer's Disease" (Apr 2014) Journal of Psychosocial Nursing & Mental Health Services 52.4 pp. 21-2
  10. ^ Majumdar et al (Jul-Sep 2013) "Hyperprolactinemia", Journal of Human Reproductive Sciences 6.3 pp.168-175
  11. ^ a b "Ergot derivatives: restricted use" (2013) WHO Drug Information 27.3 p.225
  12. ^ Helsen et al. (2013) "Ergotamine-Induced Pleural and Pericardial Effusion Successfully Treated with Colchicine", Acta Clinica Belgica 68.2 pp.113-5
  13. ^ Steinhilber, D.; Schubert-Zsilavecz, M.; Roth, H. J. (2005). Medizinische Chemie (in German). Stuttgart, Germany: Deutscher Apotheker Verlag. p. 142.  

External links

  • Ergoloid Mesylates (University of Maryland Medical Center)
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.